PE20121179A1 - Forma cristalina de hemifumarato de alisquireno - Google Patents
Forma cristalina de hemifumarato de alisquirenoInfo
- Publication number
- PE20121179A1 PE20121179A1 PE2012000369A PE2012000369A PE20121179A1 PE 20121179 A1 PE20121179 A1 PE 20121179A1 PE 2012000369 A PE2012000369 A PE 2012000369A PE 2012000369 A PE2012000369 A PE 2012000369A PE 20121179 A1 PE20121179 A1 PE 20121179A1
- Authority
- PE
- Peru
- Prior art keywords
- alisquiren
- hemifumarate
- degrees
- crystal form
- crystal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
REFERIDA A UNA FORMA DE CRISTAL DE HEMIFUMARATO DE ALISQUIRENO, DENOMINADA COMO MODIFICACION B, CARACTERIZADA POR UN PATRON DE DIFRACCION DE RAYOS X EN POLVO QUE MUESTRA LOS SIGUIENTES PICOS PRINCIPALES DADOS EN GRADOS 2 TETA +/- 0.3 GRADOS: 3.8, 6.5, 7.7, 8.0, 15.6 y 17.4. REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHO CRISTAL ES UNA FORMA MAS ESTABLE Y DE MEJORES PROPIEDADES DESEADAS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06123642 | 2006-11-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20121179A1 true PE20121179A1 (es) | 2012-09-13 |
Family
ID=37907983
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2012000369A PE20121179A1 (es) | 2006-11-07 | 2007-11-05 | Forma cristalina de hemifumarato de alisquireno |
PE2007001518A PE20081157A1 (es) | 2006-11-07 | 2007-11-05 | Forma cristalina de hemifumarato de alisquireno |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2007001518A PE20081157A1 (es) | 2006-11-07 | 2007-11-05 | Forma cristalina de hemifumarato de alisquireno |
Country Status (25)
Country | Link |
---|---|
US (1) | US8119841B2 (es) |
EP (1) | EP2079463A1 (es) |
JP (1) | JP2010508370A (es) |
KR (1) | KR20090083918A (es) |
CN (1) | CN101594857B (es) |
AR (1) | AR063560A1 (es) |
AU (1) | AU2007323465B2 (es) |
BR (1) | BRPI0718546A2 (es) |
CA (1) | CA2668828A1 (es) |
CL (1) | CL2007003194A1 (es) |
CO (1) | CO6180428A2 (es) |
EC (1) | ECSP099385A (es) |
GT (1) | GT200900116A (es) |
IL (1) | IL198470A0 (es) |
MA (1) | MA30921B1 (es) |
MX (1) | MX2009004885A (es) |
MY (1) | MY148758A (es) |
NO (1) | NO20092102L (es) |
NZ (1) | NZ577320A (es) |
PE (2) | PE20121179A1 (es) |
RU (1) | RU2466982C2 (es) |
TN (1) | TN2009000174A1 (es) |
TW (1) | TW200827326A (es) |
WO (1) | WO2008061622A1 (es) |
ZA (1) | ZA200902941B (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2220031A1 (en) * | 2007-11-13 | 2010-08-25 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of aliskiren hemifumarate and process for preparation thereof |
KR101579993B1 (ko) | 2008-01-23 | 2015-12-23 | 노파르티스 아게 | 이마티닙을 이용한 티로신 키나제 수용체 kit에 의해 매개되는 증식성 질환의 치료를 최적화하는 방법 |
EP2143425A1 (de) * | 2008-07-11 | 2010-01-13 | Ratiopharm GmbH | Direktverpresste Aliskiren-Tabletten |
JO3239B1 (ar) * | 2008-09-22 | 2018-03-08 | Novartis Ag | تركيبات جالينية من مركبات عضوية |
AR073651A1 (es) * | 2008-09-24 | 2010-11-24 | Novartis Ag | Formulaciones galenicas de compuestos organicos |
CA2951479A1 (en) * | 2008-12-18 | 2010-07-15 | Novartis Ag | Hemifumarate salt of 1-[4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidine-3-carboxylic acid |
WO2010089105A2 (en) | 2009-02-05 | 2010-08-12 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Moisture-activated granulation process |
CA2724152A1 (en) * | 2009-02-05 | 2010-08-12 | Teva Pharmaceutical Industries Ltd. | Solid state forms of aliskiren compounds |
WO2011028919A2 (en) | 2009-09-03 | 2011-03-10 | Teva Pharmaceutical Industries Ltd. | Solid forms of aliskiren hemifumarate and processes for preparation thereof |
CN102617392B (zh) * | 2011-01-28 | 2015-04-01 | 博瑞生物医药技术(苏州)有限公司 | 一种阿利克仑半富马酸盐晶型ⅰ的制备方法 |
ITMI20111291A1 (it) * | 2011-07-11 | 2013-01-12 | Djada Pharmaceutical Sa | Aliskiren emifumarato etil acetato solvato |
ITMI20111290A1 (it) | 2011-07-11 | 2013-01-12 | Djada Pharmaceutical Sa | Aliskiren emifumarato, forma cristallina e solido amorfo |
CN103172533B (zh) * | 2011-12-20 | 2016-05-04 | 博瑞生物医药(苏州)股份有限公司 | 一种阿利克仑半富马酸盐的新晶型及其制备方法和用途 |
JP6007096B2 (ja) * | 2011-12-28 | 2016-10-12 | エルメッド エーザイ株式会社 | 安定化カンデサルタンシレキセチル含有物の製造方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY119161A (en) * | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
IL153717A0 (en) | 2000-07-05 | 2003-07-06 | Speedel Pharma Ag | Process for teh preparation of substituted octanoyl amides |
NZ536555A (en) * | 2002-05-17 | 2007-03-30 | Novartis Ag | Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic |
MY148773A (en) * | 2004-03-17 | 2013-05-31 | Novartis Ag | Galenic formulations of organic compounds |
GB0419361D0 (en) * | 2004-08-31 | 2004-10-06 | Novartis Ag | Organic compounds |
-
2007
- 2007-11-05 BR BRPI0718546-4A patent/BRPI0718546A2/pt not_active IP Right Cessation
- 2007-11-05 RU RU2009121651/04A patent/RU2466982C2/ru not_active IP Right Cessation
- 2007-11-05 AR ARP070104914A patent/AR063560A1/es not_active Application Discontinuation
- 2007-11-05 US US12/312,320 patent/US8119841B2/en not_active Expired - Fee Related
- 2007-11-05 MX MX2009004885A patent/MX2009004885A/es active IP Right Grant
- 2007-11-05 AU AU2007323465A patent/AU2007323465B2/en not_active Ceased
- 2007-11-05 PE PE2012000369A patent/PE20121179A1/es not_active Application Discontinuation
- 2007-11-05 KR KR1020097011654A patent/KR20090083918A/ko not_active Application Discontinuation
- 2007-11-05 PE PE2007001518A patent/PE20081157A1/es not_active Application Discontinuation
- 2007-11-05 NZ NZ577320A patent/NZ577320A/en not_active IP Right Cessation
- 2007-11-05 WO PCT/EP2007/009573 patent/WO2008061622A1/en active Application Filing
- 2007-11-05 EP EP07856175A patent/EP2079463A1/en not_active Withdrawn
- 2007-11-05 CN CN2007800492907A patent/CN101594857B/zh not_active Expired - Fee Related
- 2007-11-05 JP JP2009535613A patent/JP2010508370A/ja active Pending
- 2007-11-05 MY MYPI20091725A patent/MY148758A/en unknown
- 2007-11-05 CA CA002668828A patent/CA2668828A1/en not_active Abandoned
- 2007-11-06 CL CL200703194A patent/CL2007003194A1/es unknown
- 2007-11-06 TW TW096141915A patent/TW200827326A/zh unknown
-
2009
- 2009-04-29 ZA ZA200902941A patent/ZA200902941B/xx unknown
- 2009-04-30 IL IL198470A patent/IL198470A0/en unknown
- 2009-05-05 TN TNP2009000174A patent/TN2009000174A1/fr unknown
- 2009-05-06 GT GT200900116A patent/GT200900116A/es unknown
- 2009-05-27 MA MA31922A patent/MA30921B1/fr unknown
- 2009-05-28 NO NO20092102A patent/NO20092102L/no not_active Application Discontinuation
- 2009-06-04 CO CO09057907A patent/CO6180428A2/es not_active Application Discontinuation
- 2009-06-04 EC EC2009009385A patent/ECSP099385A/es unknown
Also Published As
Publication number | Publication date |
---|---|
MA30921B1 (fr) | 2009-11-02 |
NO20092102L (no) | 2009-07-30 |
BRPI0718546A2 (pt) | 2013-11-19 |
AU2007323465B2 (en) | 2011-08-04 |
CN101594857A (zh) | 2009-12-02 |
AR063560A1 (es) | 2009-02-04 |
MX2009004885A (es) | 2009-05-19 |
US20100048716A1 (en) | 2010-02-25 |
CN101594857B (zh) | 2012-10-31 |
US8119841B2 (en) | 2012-02-21 |
IL198470A0 (en) | 2010-02-17 |
AU2007323465A1 (en) | 2008-05-29 |
JP2010508370A (ja) | 2010-03-18 |
TN2009000174A1 (en) | 2010-10-18 |
RU2466982C2 (ru) | 2012-11-20 |
CO6180428A2 (es) | 2010-07-19 |
WO2008061622A1 (en) | 2008-05-29 |
MY148758A (en) | 2013-05-31 |
RU2009121651A (ru) | 2010-12-20 |
ECSP099385A (es) | 2009-07-31 |
KR20090083918A (ko) | 2009-08-04 |
NZ577320A (en) | 2012-01-12 |
TW200827326A (en) | 2008-07-01 |
GT200900116A (es) | 2011-06-07 |
EP2079463A1 (en) | 2009-07-22 |
CA2668828A1 (en) | 2008-05-29 |
CL2007003194A1 (es) | 2008-06-13 |
ZA200902941B (en) | 2010-03-31 |
PE20081157A1 (es) | 2008-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20121179A1 (es) | Forma cristalina de hemifumarato de alisquireno | |
CL2011002248A1 (es) | Composicion farmaceutica oral de liberacion inmediata que comprende oxicodona y naloxona en una proporcion 2:1 en peso; uso de la composicion farmaceutica para tratar dolor intercurrente en paciente que sufren de dolor. | |
CO6410279A2 (es) | Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente. | |
CL2010001348A1 (es) | Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad. | |
UY32427A (es) | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma | |
AR088755A1 (es) | Formas solidas de un inhibidor de disociacion transtiretina | |
CU23743B7 (es) | Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hematológicas | |
SV2011004019A (es) | 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso | |
CL2007003609A1 (es) | Compuestos derivados de dihidropiridinas sustituidas; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; proceso para producir la composicion farmaceutica; y uso en el tratamiento de una enfermedad mejorada con la inhibicion | |
CO6450612A2 (es) | Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750 | |
EA201291310A1 (ru) | Композиция ингибитора jak для местного применения | |
UY31228A1 (es) | Ariloxazoles sustituidos y su uso | |
ECSP088904A (es) | Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina | |
CR20120620A (es) | Nuevas formas de rifaximina y usos de las mismas | |
DOP2010000282A (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa | |
UY31922A (es) | Compuestos | |
UY31990A (es) | Nuevos derivados | |
SV2009002953A (es) | Nuevos derivados de furopirimidina aciclicos sustituidos y su uso | |
AR065554A1 (es) | Formas cristalinas de un compuesto 8- azabiciclo (3,2,1) octano. procesos de obtencion y composiciones farmaceuticas. | |
DOP2010000400A (es) | 7-sulfanilmetil-,7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos | |
ECSP10010578A (es) | Composicion farmaceutica 271 | |
AR066936A1 (es) | 3 - (2r - tetrahidrofuril - metil) - 2 - tioxantina. composiciones farmaceuticas. | |
AR083095A1 (es) | Cocristal de aprepitant l-prolina y composicion farmaceutica | |
ECSP088153A (es) | Nuevos derivados de piperidina | |
BRPI0813420A2 (pt) | uso de uma preparação, composição, método cosmético de tratamento de emagrecimento, e, método de um tratamento terapêutico para reduzir a quantidade de lipídeos armazenados pelos adipócitos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |